Abstract
In the search for new chelation therapy drugs for the treatment of metal intoxications, some new polyphosphonated chelating ligands have been synthesized. They were obtained by means of an Arbuzov reaction followed by addition of the corresponding dialkylphosphite. The regioselective dealkylation was then carried out by using trimethylsilyl halide.
Keywords: tetraphosphonate, chelating agents, restrained geometry, partial deprotection
Letters in Organic Chemistry
Title: Synthesis of New Ligands Derived from Polyphosphonates Partial Esters
Volume: 1 Issue: 1
Author(s): Pascale Even, Erwann Guenin, Mounya Benramdame, Patricia Quidu, Driss El Manouni and Marc Lecouvey
Affiliation:
Keywords: tetraphosphonate, chelating agents, restrained geometry, partial deprotection
Abstract: In the search for new chelation therapy drugs for the treatment of metal intoxications, some new polyphosphonated chelating ligands have been synthesized. They were obtained by means of an Arbuzov reaction followed by addition of the corresponding dialkylphosphite. The regioselective dealkylation was then carried out by using trimethylsilyl halide.
Export Options
About this article
Cite this article as:
Even Pascale, Guenin Erwann, Benramdame Mounya, Quidu Patricia, Manouni El Driss and Lecouvey Marc, Synthesis of New Ligands Derived from Polyphosphonates Partial Esters, Letters in Organic Chemistry 2004; 1 (1) . https://dx.doi.org/10.2174/1570178043488563
DOI https://dx.doi.org/10.2174/1570178043488563 |
Print ISSN 1570-1786 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6255 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cancer Prevention and Therapy in a Preclinical Mouse Model: Impact of FHIT Viruses
Current Gene Therapy Luminescent Silica Nanoparticles for Cancer Diagnosis
Current Medicinal Chemistry MiRNA-145 and Its Direct Downstream Targets in Digestive System Cancers: A Promising Therapeutic Target
Current Pharmaceutical Design The Chemokine Receptor CXCR4 as a Therapeutic Target for Several Diseases
Mini-Reviews in Medicinal Chemistry The Effects of Curcumin on Immune Responses
Current Bioactive Compounds A Scientometrics Analysis and Visualization of Depressive Disorder
Current Neuropharmacology Molecular Docking of 4-ethoxychalcones on Oxidoreductase/Pirin Inhibitors and Cytotoxic Evaluation on Breast/Skin Cancer Cell Lines
Letters in Drug Design & Discovery Arylsulfonylhydrazone Induced Apoptosis in MDA-MB-231 Breast Cancer Cells
Letters in Drug Design & Discovery Metabolic Syndrome X is a Low-Grade Systemic Inflammatory Condition with its Origins in the Perinatal Period
Current Nutrition & Food Science Pernicious Anemia: Fundamental and Practical Aspects in Diagnosis
Cardiovascular & Hematological Agents in Medicinal Chemistry HOX Genes as Potential Markers of Circulating Tumour Cells
Current Molecular Medicine Metronomic Therapy for Multi Relapsed/Refractory Lymphoma. A Pilot Study
Current Angiogenesis (Discontinued) HSV-1 Viral Oncolysis and Molecular Imaging with PET
Current Cancer Drug Targets Cytotoxic Constituents from the Bark of Erythrina poeppigiana Against the MCF-7 Breast Cancer Cell Lines
The Natural Products Journal Nuclear Hormone Receptor Signals as New Therapeutic Targets for Urothelial Carcinoma
Current Cancer Drug Targets Immunotherapeutic Approaches in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry ADR in Journals: Are They Translated into Regulatory Frameworks?
Current Drug Safety Modulation of the Human Gut Microflora Towards Improved Health Using Prebiotics - Assessment of Efficacy
Current Pharmaceutical Design Transport of Bupropion and its Metabolites by the Model CHO and HEK293 Cell Lines
Drug Metabolism Letters Targeting the Immune System in Cancer
Current Pharmaceutical Biotechnology